Advertisement

Surgical Endoscopy

, Volume 30, Issue 5, pp 1983–1987 | Cite as

Non-alcoholic fatty liver disease resolution following sleeve gastrectomy

  • Ardeshir Algooneh
  • Sulaiman Almazeedi
  • Salman Al-SabahEmail author
  • Maha Ahmed
  • Feras Othman
Article

Abstract

Background

Non-alcoholic fatty liver disease (NAFLD), a disease highly prevalent among the morbidly obese population, is one of the most common causes of chronic liver disease today. The purpose of this study was to observe the effect of laparoscopic sleeve gastrectomy (LSG) on the resolution of NAFLD.

Methods

A retrospective study was conducted of 84 patients diagnosed with NAFLD prior to undergoing LSG. The diagnosis of NAFLD was achieved based on transabdominal ultrasonographic imaging as per the 2012 joint guidelines for the diagnosis of NAFLD (American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology). The patients had follow-up anthropometric measurements and were re-evaluated with postoperative ultrasounds at different time frames to assess the resolution of the disease.

Results

The median age of the patients was 44 (17–62), and 66.7 % were female. Average time since surgery was 3.3 years (range 1–5 years). The mean pre- and postoperative BMIs were 46.6 ± 7.8 and 33.0 ± 7.1, respectively, with a mean percent excess weight loss (%EWL) of 55.7 % ± 23.0. A total of 47 (56 %) patients showed complete resolution of NAFLD postoperatively. Multivariate analysis showed a significant resolution of NAFLD in patients achieving >50 % EWL (OR 10.1; p < 0.001) after controlling for age and sex.

Conclusions

Weight loss after LSG effectively resolved NAFLD in more than half of the obese patients in this study and can prove to be a useful tool in tackling the disease in the future.

Keywords

Bariatric Sleeve gastrectomy Obesity NAFLD Metabolic surgery 

Notes

Acknowledgments

The authors would like to thank all who have contributed to making this study possible, most notably Dr. Hind Almazeedi.

Compliance with ethical standards

Disclosures

The author Ardeshir Algooneh declares having no conflicts of interest or financial ties to disclose. The author Sulaiman Almazeedi declares having no conflicts of interest or financial ties to disclose. The author Salman Al-Sabah declares having no conflicts of interest or financial ties to disclose. The author Maha Ahmed declares having no conflicts of interest or financial ties to disclose. The author Feras Othman declares having no conflicts of interest or financial ties to disclose.

References

  1. 1.
    Lee D (2007) Obesity can lead to fatty liver a silent killer, editorial review Aug 2007. http://www.medicinenet.com/script/main/art.asp?articlekey=46582. Accessed 15 Feb 2015
  2. 2.
    Angulo P (2007) GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 25:883–889CrossRefPubMedGoogle Scholar
  3. 3.
    Law K, Brunt E (2010) Nonalcoholic fatty liver disease. Clin Liver Dis 14:591–604CrossRefPubMedGoogle Scholar
  4. 4.
    Oh M, Winn J, Poordad F (2008) Review article: diagnosis and treatment of nonalcoholic fatty liver disease. Aliment Pharmacol Ther 28(5):503–522CrossRefPubMedGoogle Scholar
  5. 5.
    Vernon G, Baranova A, Younossi Z (2011) Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34:274–285CrossRefPubMedGoogle Scholar
  6. 6.
    Day C (2011) Non-alcoholic fatty liver disease: a massive problem. Clin Med 11:176–178CrossRefGoogle Scholar
  7. 7.
    Zelber-Sagi S, Ratziu V, Oren R (2011) Nutrition and physical activity in NAFLD: an overview of the epidemiological evidence. World J Gastroenterol 17:3377–3389CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Adams L, Feldstein A (2010) Nonalcoholic steatohepatitis: risk factors and diagnosis. Expert Rev Gastroenterol Hepatol 4:623–635CrossRefPubMedGoogle Scholar
  9. 9.
    Lonardo A, Lombardini S, Ricchi M et al (2005) Review article: hepatic steatosis and insulin resistance. Aliment Pharmacol Ther 22(Suppl. 2):64–70CrossRefPubMedGoogle Scholar
  10. 10.
    Krawczyk M, Bonfrate L, Portincasa P (2010) Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 24:695–708CrossRefPubMedGoogle Scholar
  11. 11.
    Lonardo A, Bellentani S, Ratziu V et al (2011) Insulin resistance in nonalcoholic steatohepatitis: necessary but not sufficient—death of a dogma from analysis of therapeutic studies? Expert Rev Gastroenterol Hepatol 5:279–289CrossRefPubMedGoogle Scholar
  12. 12.
    American liver foundation. Non alcoholic fatty liver disease. January 2015. http://www.liverfoundation.org/abouttheliver/info/nafld. Accessed 20 Feb 2015
  13. 13.
    Sasaki A, Nitta H, Otsuka K (2014) Bariatric surgery and non-alcoholic fatty liver disease: current and potential future treatments. October 2014. http://journal.frontiersin.org/article/10.3389/fendo.2014.00164/full. Accessed 20 Feb 2015
  14. 14.
    Digestive Disease Week. Weight-loss surgery can reduce liver damage: study shows reversal of early-stage liver fibrosis after bariatric surgery. May 2014. http://www.ddw.org/news/articles/2014/05/06/weight-loss-surgery-can-reduce-liver-damage. Accessed 20 Feb 2015
  15. 15.
    Chalasani N, Younossi Z, Lavine J et al (2012) The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55(6):2005–2023CrossRefPubMedGoogle Scholar
  16. 16.
    Johnson B, Blackhurst D, Latham B et al (2013) Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. J Am Coll Surg 216(4):545–556; discussion 556–558Google Scholar
  17. 17.
    Freedman D, Ron E, Ballard-Barbash R et al (2006) Body mass index and all-cause mortality in a nationwide US cohort. Int J Obes (Lond) 30(5):822–829CrossRefGoogle Scholar
  18. 18.
    Vogel J, Franklin B, Zalesin K (2007) Reduction in predicted coronary heart disease risk after substantial weight reduction after bariatric surgery. Am J Cardiol 99(2):222–226CrossRefPubMedGoogle Scholar
  19. 19.
    Karcz W, Krawczykowski D, Kuesters S et al (2011) Influence of sleeve gastrectomy on NASH and type 2 diabetes mellitus. J Obes 765473Google Scholar
  20. 20.
    Fabbrini E, Sullivan S, Klein S (2010) Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51(2):679–689CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Dixon J, Bhathal P, Hughes N et al (2004) Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 39(6):1647–1654CrossRefPubMedGoogle Scholar
  22. 22.
    Chavez-Tapia N, Tellez-Avila F, Barrientos-Gutierrez T et al (2010) Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 20(1):CD007340Google Scholar
  23. 23.
    Mattar S, Velcu L, Rabinovitz M et al (2005) Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 242(4):610–617PubMedPubMedCentralGoogle Scholar
  24. 24.
    Taitano A, Markow M, Finan J et al (2015) Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis. J Gastrointest Surg 19(3):429–437CrossRefPubMedGoogle Scholar
  25. 25.
    Vuppalanchi R, Chalasan N (2009) Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology 49(1):306–317CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Aithal G, Thomas J, Kaye P et al (2008) Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 135(4):1176–1184CrossRefPubMedGoogle Scholar
  27. 27.
    Mathurin P, Gonzalez F, Kerdraon O et al (2006) The evolution of severe steatosis after bariatric surgery is related to insulin resistance. Gastroenterology 130(6):1617–1624CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Ardeshir Algooneh
    • 1
  • Sulaiman Almazeedi
    • 1
  • Salman Al-Sabah
    • 1
    Email author
  • Maha Ahmed
    • 2
  • Feras Othman
    • 1
  1. 1.Department of Surgery, Amiri HospitalKuwait Ministry of HealthKuwaitKuwait
  2. 2.Department of Radiology, Amiri HospitalKuwait Ministry of HealthKuwaitKuwait

Personalised recommendations